Institute of Psychiatry



Staff interests associated with the school's research programmes and research groups

Interests:
The effects of risk communication on health behaviour and underlying cognitive and emotional mechanisms; The role of automatic or non-reflective processes in behaviour change
Tel:
020 7188 0192
Email:
Interests:
Novel substances of abuse (eg mephedrone), dance drug epidemiological studies, cannabis use disorders, assesssment of patient knowledge and understanding of treatment interventions and diversion of opioid pharmacotherapies
Tel:
020 7848 0207
Email:
Website:
Interests:
Alcohol screening and brief interventions
Email:
Interests:
The development of alcohol and substance misuse in adolescence, comorbidity of substance misuse and psychological symptoms. Exploring mechanisms of risk using multivariate longitudinal, cognitive and behavioural genetic approaches.
Email:
Website:
Interests:
Alcohol, epidemiology of alcohol misuse, randomised control trials
Tel:
0207 848 0817
Email:
Website:
Interests:
Smoking cessation. Tobacco research. Addiction psychology.
Tel:
020 7848 0440
Email:
Website:
Interests:
Professor Emeritus of Addiction Behaviour
Tel:
020 7848 0853
Website:
Interests:
I specialise in mental health service research, which in itself looks at the development and evaluation of services for people with mental health and addictions problems. My particular interest is in accessing service user views and their involvement to gain a wider picture of the impact and effectiveness of health services and practices involved in health care provision. I am particularly interested in the use of qualitative methodology to achieve these aims. Projects I am involved in include, evaluation of inpatient alternatives to hospital for people with acute mental health problems; implementation of the recovery model in mental health services; the role of therapeutic relationships in health care provision and innovation on inpatient wards. I currently manage a randomised controlled trial of assertive community treatment for people with alcohol dependence.
Website:
Interests:
The behavioural analysis of drug dependence has been Ian Stolerman’s major research activity. He has studied a variety of drugs including opiates, psychomotor stimulants, benzodiazepines and alcohol but is best known for research on nicotine dependence on which he has worked for over 30 years. In early studies he obtained evidence that people smoked tobacco to obtain the effects of nicotine and that nicotine was an addictive drug. Subsequent work examined the receptor mechanisms and brain sites through which nicotine acts to bring about dependence and the neurotransmitters involved in mediating its actions downstream from nicotinic receptors. Recent studies have focused on (1) the abiliy of nicotine to enhance cognition in an animal model for assessing attention and (2) on the effects of prenatal exposure to nicotine on the maturation and development of the offspring and on their behaviour during adolescence and adulthood. Another important line of work led to advances in drug discrimination methodology and the first systematic studies of the discrimination of abused drug mixtures.
Tel:
020 7848 0370
Email:
Interests:
Current research activities:
1. Improving response to alcohol dependence in general hospitals
2. Management of GBL dependence and withdrawal
3. Treatment of opioid dependence, particularly use of injectable treatment

Website:
Interests:
John Marsden is a clinical research psychologist with a research focus on the study of behavioural and pharmacological therapies for substance use disorders. He has held professional appointments in the addictions field since 1987. He has research interests in treatment systems research, psychometrics, and psychiatric epidemiology. John is the European editor of Addiction. He was a member of the Advisory Council on the Misuse of drugs (2005-2009) and a founding member of the Independent Scientific Committee on Drugs.

Tel:
020 7848 0830
Email:
Website:
Interests:
Professor John Strang is the Head of the Addictions Department. Interests include Addiction treatment studies, ConMan research programme of contingency management incentives for health in addiction treatments, medication trials, N-ALIVE randomised trial of naloxone to prevent heroin overdose deaths, policy analysis, psychosocial and abstinence recovery trials, RIOTT randomised trial of supervised heroin prescribing, study of overdose deaths and prevention
Tel:
020 7848 0438
Email:
Website:
Interests:
I have 5 PhD students investigating nicotine metabolism; methadone prescribing in pregnancy; addicted health care professionals; ecstasy profiling and; craving in co-dependence with alcohol and methadone.

Addiction, biomarkers, MDMA (ecstasy) use, methadone, methadone and pregnancy, pharmacogenetics, pharmacokinetics, postgraduate education, substance misuse
Tel:
020 7848 0441
Email:
Website:
Interests:
Professor of Addiction Psychiatry
Tel:
020 3228 1907
Email:
Tel:
020 7848 0138
Email:
Interests:
Contingency management, injectable opiates.
Tel:
020 7848 0359
Email:
Interests:
Novel recreational drugs/legal highs, the role of Information and Communication Technologies in drug abuse prevention and treatment, alcohol screening and brief interventions.
Website:
Interests:
My research interest focus on cognitive and genetic risk factors for substance misuse. Using high risk research designs, I explore the role of specific genetic, temperament and cognitive factors that render certain individuals susceptible to drug and alcohol abuse. This research has implications for the development of novel approaches to treatment and prevention of substance misuse. I am currently investigating the efficacy of interventions targeting known risk factors for substance use disorders and patterns of co-morbidity.
Tel:
020 848 0836
Email:
Website:
Interests:
addiction, culture and substance misuse, initiation and maintenance of behaviour change, outcome measurement, psychological impact of trauma and the association between trauma and addictive behaviours
Email:
Interests:
Statistics; scale development; multiple comparison methods; model selection; structural equation modelling.
Tel:
020 7848 0309
Email:
Website:
Tel:
(020) 71888091 (020) 32992746 mobile:07400077797
Email:
Website:
Interests:
The BRC Bioinformatics team have developed expertise in the analysis, integration and modeling of complex large molecular datasets such as expression and SNP arrays, next generation sequencing, approaches for network (gene regulatory, co-expression and protein interaction), pathway studies and text mining of Electronic Patient Records (EPR) providing novel insights into disease mechanisms and biomarker discovery.

We are performing a range of studies through the combined analysis of clinical, imaging, proteomics, transcriptomics and genomic datasets, and have multiple active academic and industrial collaborations.

For a full publication list see either link below (the list provided on this page is incomplete):

http://www.iop.kcl.ac.uk/staff/profile/?go=12524

or

http://www.researcherid.com/rid/C-9269-2011

Email:
Website:
Interests:
Spatial statistics, especially the analysis of spatial cell pattern and the analysis of repeated measurements; cluster analysis
Tel:
020 7848 0313
Email:
Website:
Interests:
Attention deficit hyperactivity disorder (ADHD), executive function, functional magnetic resonance imaging (fMRI), time estimation.
Tel:
020 7848 0755
Fax:
020 7708 5800
Website:
Interests:
ADHD; developmental psychiatry; epidemiology; mood disorders; oppositionality; comorbidity.
Tel:
020 7848 0302
Email:
Website:
Interests:
Neuropsychiatric disorders in childhood; autism; typical and atypical brain development; structural neuroimaging; genetics.
Tel:
020 7848 0651
Email:
Website:
Interests:
Learning disabilities; ADHD; autism; antisocial behaviour; genetics; epidemiology.
Tel:
020 7848 5312
Email:
Website:
Interests:
Developmental neuropsychiatry, epilepsy, obsessive compulsive disorder (OCD), Tourette Syndrome.
Tel:
020 3228 5222
Fax:
020 7708 5800
Website:
Interests:
Brain imaging of normal development and child psychiatric disorders; neuropsychology of impulsiveness.
Tel:
020 7848 0463
Email:
Website:
Interests:
Developmental psychopathology of behavioural and emotional disorders of childhood; family processes and parenting.
Website:
Interests:
Neuropsychiatric disorders in childhood; autism; communication disorders; behavioural phenotypes of genetic disorders.
Tel:
020 7848 5325
Email:
Website:
Interests:
Psychiatric consequences of chronic neurodevelopmental disorders.
Website:
Interests:
Conduct disorder and antisocial behaviour; parenting interventions; attachment; adoption and fostering.
Tel:
020 7848 0746
Email:
Website:
Interests:
Mendelian and complex disease genetics in neurological diseases (especially motor neuron disease); Epidemiology of motor neuron disease; Genetics statistics; RNA processing genes and proteins.
Tel:
020 7848 5172
Email:
Website:
Interests:
Molecular neuropathology.
Email:
Interests:
Molecular genetics, RNA editing, epilepsy, schizophrenia.
Website:
Interests:
Functional MRI, structural and volumetric MRI, diffusion MRI, MRS, genetics-imaging correlates, image processing and e-learning.
Tel:
020 7919 3055
Email:
Website:
Interests:
Traumatic brain injury; cortical spreading depression; experimental stroke; fluorescence imaging; speckle imaging; penumbra; neurocritical care.
Tel:
020 3299 3282/1715
Email:
Website:
Interests:
Basic neurophysiology of human epilepsy, surgical treatment and diagnosis; surgical treatment of movement disorders.
Website:
Interests:
Understanding the molecular mechanisms of Alzheimer's disease and motor neurone disease.
Tel:
020 7848 0393
Email:
Website:
Interests:
Genetic, molecular and cellular studies in the familial motor neurone disorders including motor neuron disease (also known as amyotrophic lateral sclerosis - ALS +/- frontotemporal dimentia), spinal muscular atrophy and herediatry spastic paraplegia.
Tel:
020 7848 5180
Email:
Website:
Interests:
Brain injury pathophysiology and neuroregeneration, 1) Spreading Depression, 2) Stem cell research, 3) Neuromonitoring (microdialysis, invasive monitoring), 4) Hyperoxia (in vitro and in vivo work) and neurovascular bypass, 5) ELANA (Excimer Laser Assisted Cerebral Vascular Bypass).
Tel:
020 7772 4250
Email:
Website:
Interests:
MR Physics; structural imaging; chemical shift imaging; pulse sequence programming.
Tel:
020 7919 3043
Email:
Website:
Interests:
MS and other CNS immune disease including 1) Care of people with advanced MS, 2) Mental health needs of people with MS, 3) Ethnicity in MS, 4) Sleep and fatigue in MS, 5) Clinical trials of novel agents in the management of MS, 6) MRI in early MS/CIS with Dr Peter Brex.
Email:
Interests:
MR imaging of brain physiology and function MR imaging measurements of cerebral blood flow, modulation of physiology and cognition by psychoactive drugs.
Tel:
020 3228 3069
Email:
Website:
Interests:
The implementation and development of quantitative Magnetic Resonance Imaging (MRI) techniques including T1 and T2-mapping, Diffusion Tensor Imaging (DTI), and quantitative Magnetisation Transfer (MT) measurements, along with the apllication of such techniques in research projects covering neurodegeneration, epilepsy, stroke, psychosis, affective disorders, developmental disorders and normal brain function.
Tel:
020 3228 3059
Email:
Website:
Interests:
Role of experience-dependent plasticity in learning and disease; electrophysiology, confocal microscopy and functional magnetic resonance imaging to understand how the brain reorganises when challenged; application of this knowledge to develop treatments for acute neurological conditions such as stroke and chronic neurodegenerative diseases such as Alzheimer's disease.
Tel:
020 7848 0274
Email:
Website:
Interests:
Mechanism of human epilepsy; surgical treatment of epilepsy; Neurophysiology of human epilepsy.
Tel:
020 7848 5161
Email:
Website:
Interests:
Neuropathology of epilepsy; TDP-43 and Argyrophilic Grain Disease in MND.
Website:
Interests:
Role of the cytoskeleton in neurodegeneration especially in tauopathies eg Alzheimer's disease. Role of RNA and RNA processing in neurodegeneration. RNA-based therapies for neurodegenerative diseases.
Tel:
020 7848 0404
Email:
Website:
Interests:
Neuroimaging.
Tel:
020 7848 5152
Email:
Website:
Interests:
Transcranial magnetic stimulation, motor control, motor neurone diseases and EMG quantification.
Tel:
020 7848 5175
Email:
Website:
Interests:
Main areas of research interest/publications are Functional Neurosurgery and Neuro-oncology: 1) Imaging and targeting of brain nuclei for deep brain stimulation, 2) Outcome of patients treated with deep brain stimulation, 3) Neurophysiology and antomy of moto functional circuits, 4) New indications for neuromodulation/stimulation, 5) Alternative surgical techniques for movement disorders, 6) Improved imaging/early detection of brain tumours, 7) Outcome patients undergoing treatment for brain tumours, 8) New treatment modalities for brain tumours.
Tel:
020 3299 3285
Email:
Website:
Interests:

Activities and Interests

Headache
Guy's & St Thomas's Hospital Charity fund the Neurology & General Practice Unit for Service Delivery and Evaluation of innovation in Headache Services. Six GPs with Special Interest in Headache have been trained. Intermediate Care Clinics have been set up in Southwark and Lambeth and an evaluation published in the BJGP. Patients seen by the GP with Special Interest Service were more satisfied than patients who saw hospital-based general neurologists. The PCT was charged less for the GPwSI service than for hospital care. Further work is in progress to develop a CBT intervention for Migraine.

Prior work funded by the MRC set the stage for this by examining the reasons for referral of patients with headache to specialists. It was found that GPs referred only 2% of consulters for primary headache to neurologists. These patients reported the same level of headache severity and disability as patients managed in primary care. Referred patients expressed more fear and anxiety about their headache symptoms. GPs reported that patient pressure was important in the referral decision, and their wish for a brain scan.

A new study designed to describe the prevalence of PFO and their association with migraine, and trial clopidogrel in the prevention of migraine has begun in collaboration with John Chambers (PI), and funded by the Dunhill Trust.

Fatigue
A Wellcome Trust grant funded the third complex intervention trial by this unit for patients with chronic fatigue in primary care. This three-arm RCT of Graded Exercise, Counselling and Usual Care plus a booklet on CBT has been completed, with results presented at meetings, and papers submitted for publication.

Epilepsy
Prior work has included trial of nurse interventions for people with new and chronic epilepsy. An NIHR SDO grant funds the unit for a study titled: Can nurse-led rehabilitation for epilepsy patients prevent non-planned admissions? A comparison of cost and effectiveness of service models at two centres. This is currently recruiting patients at King's College Hospital and Guy's & St Thomas' Hospitals.
Epilepsy Bereaved is funding an epidemiological study of causes of mortality in epilepsy, using the General Practice Research Database, in collaboration with Martin Gulliford.
In collaboration with Brian Hurwitz, the Unit is hosting Maria Vaccarella, who is funded by a Marie Curie Fellowship, to explore the relationship between epilepsy in the arts and the experience of epilepsy care.

Teaching Activities

Leone Ridsdale is Director of Neurology Undergraduate Clinical Teaching, and Chair of Clinical Teaching in Year 3 for the Neurology-Opthalmology-Psychiatry Rotation. In the past, medical graduates have reported lack of competence and confidence in neurology, amounting to 'neurophobia'. KCL students do 12 a week rotation in clinical neurology, linked with psychiatry teaching. This has been evaluated, and KCL students report as much confidence in their neurology knowledge and skills, as in other Year 3 subjects. Students rated neurology as top, tied with cardiology, for interest and as the subject in which they would like to specialize (Ridsdale L, Massey R, Clark L. (2007) Preventing 'neurophobia' in medical students, and so future doctors. Practical Neurology 7:116-123).

Tel:
020 7848 5182
Email:
Website:
Interests:
Genetics of Idiopathic epilepsy and sudden death in epilepsy.
Website:
Interests:
Epilepsy research including structural and functional neuroimaging, seizure prediction, studies of single neurons in vivo in human subjects, transcranial magnetic brain stimulation and EEG.
Tel:
020 7848 5364
Email:
Website:
Interests:
Structural and functional neuroimaging and psychometric testing of acute and chronic painful conditions; development of painful conditions in healthy individuals.
Tel:
020 7919 3047
Email:
Website:
Interests:
Clinical trials, systematic reviews, and quality of life issues in muscle disease.
Tel:
020 3299 8352
Email:
Interests:
Understanding drug action in the brain using fMRI, PET and EEG.
Tel:
020 3228 3053
Email:
Website:
Interests:
Neuroimaging (PET, MRI) in motor neurone disease and Parkinsonian disorders, clinical trials and the biology and molecular pathology of neurodegeneration.
Tel:
020 7848 5187
Email:
Website:
Interests:
NHS consultant with a special interest in Cerebrovascular disorders; Run the Neurovascular clinic with Dr Tony Todd; Participate in the International Carotid Stenting Study and IST 3.
Email:
Interests:
Parkinson's Disease and nonmotor problems; sleep disorders as applied to movement disorders; restless leg syndrome, RNA.
Website:
Interests:
Systematic reviews of treatment for neuromuscular disease.
Tel:
020 7848 6122
Email:
Website:
Interests:
Surgical treatment of epilepsy; vagus nerve stimulation; outcome assessment in neurosurgery; deep brain stimulation.
Email:
Website:
Interests:
Clinical neurophysiology; epilepsy.
Tel:
020 7848 5152
Email:
Website:
Interests:
Dr Hadden is interested in acute and chronic inflammatory neuropathies. These include Guillain-Barré Syndrome, chronic inflammatory demyelinating polyradiculoneuropathy, paraproteinaemic demyelinating neuropathy, and vasculitic neuropathy. He continues to participate in clinical treatment trials, and has written clinical treatment guidelines through his membership of task forces of international experts. He runs the peripheral nerve service for the region of Kent and south-east London.
Email:
Interests:
Neurofibromatosis 1 and 2, malignant peripheral nerve sheath tumours and PET.
Email:
Website:
Interests:
Distribution of TDP-43 in MND and related disorders; timing of traumatic head injury.
Email:
Website:
Interests:
Functional, anatomical and metabolic neuroimaging; pre-clinical models of CNS disorders.
Tel:
020 3228 3060
Fax:
020 3228 2116
Email:
Website:
Interests:
Movement disorders and sleep disorders.
Email:
Interests:
Collaborative research studies looking into the clinical aspects of Huntingdon's disease with a hope that this will lead to clinical trials of disease modifying agents. Priniple Investigator of EURO-HD Registry study and a co-investigator on HSG-PREDICT study.
Tel:
020 7188 7255
Email:
Interests:
Neuropathology of neurodegeneration; motor neurone disease; Alzheimer's disease; dementia with Lewy Bodies.
Tel:
020 7848 0636
Email:
Website:
Interests:
Functional and structural MRI, schizophrenia, schizotypy, genetics, psychopharmacology and eye movements.
Tel:
020 3228 3057
Email:
Website:
Interests:
Using ERPs and fMRI to investigate antisocial behaviour.
Website:
Interests:
Developmental neurobiology of aggression; personality disorders; antisocial behaviour.
Email:
Interests:
Epidemiology and aetiology of association between serious mental disorders including schizophrenia, and increased risk of violence..
Website:
Interests:
Neurobiology of antisocial and criminal behaviour in people suffering from psychosis.
Tel:
020 7848 0680
Email:
Interests:
Examining the aetiology of schizophrenia using ERR, sMRI fMRI and genetic analysis.
Tel:
020 7848 0964
Email:
Website:
Interests:
Cognitive psychological and functional imaging studies of reality distortion in psychosis, social and antisocial cognition.
Tel:
020 7848 0637
Email:
Website:
Tel:
020 7848 0700
Fax:
020 7848 0650
Website:
Interests:
Investigating the proximal and distal determinants of antisocial and violent behaviour among persons who develop and who have schizophrenia and the most effective means to engage these individuals in treatment programmes. Neurobiological investigations of individuals with early-onset and stable antisocial behaviour across the life-span.
Tel:
020 7848 0124
Email:
Website:
Interests:
Physical health in SMI, management of acute violence, endocrine effects of antipsychotics.
Email:
Interests:
Investigating the long term outcome of Attention Deficit Hyperactivity Disorder; investigating and evaluating treatment programmes for antisocial and violent behaviour.
Tel:
020 7848 5280
Email:
Website:
Interests:
Evaluation of community mental health services in forensic mental health, clinical trials in forensic psychiatry, evaluation of offender treatment programmes in forensic mental health care, investigation of ethnicity and pathways into secure care, study of suicide and needs assessment in prisoners.
Tel:
020 7848 0584
Email:
Website:
Interests:
Primary care; mental health care, notably detection and management of depression; educational initiatives for general practice.
Tel:
020 7848 0150
Email:
Website:
Interests:
Ageing and dementia in developing coutries, perinatal psychiatry, addiction.
Tel:
020 7848 0340
Email:
Website:
Interests:

Epidemiology of psychosis
Social factors in the aetiology, course and outcome of psychosis
Culture, ethnicity and mental disorder
Illness behaviour and health service utilisation
Philosophy and sociology of mental illness
Research methodology

Tel:
020 7848 0351
Fax:
020 7848 5056
Email:
Website:
Interests:
Psychiatric aspects of primary care and training primary care staff.
Tel:
020 7848 0735
Email:
Interests:
User-led research; social and cultural analysis of mental problems and mental health systems.
Tel:
020 7848 5066
Email:
Website:
Interests:
Pathways into care of ethnic groups, health care beliefs and help-seeking, common mental disorders in different ethnic groups, cultural identity in adolescents, deliberate self-harm.
Tel:
020 7848 0047
Email:
Website:
Interests:
Ethical aspects of community care (coercion, mental health legislation), carers, care planning, clinical governance.
Tel:
020 7848 0096
Email:
Website:
Interests:
Mental health services research, needs assessment, mental health policy, community care.
Tel:
020 7848 0736
Email:
Website:
Interests:
The development and application of qualitative research methodologies, carer research, the impact of dementia on carers, inventions to improve the quality of life for carers.
Tel:
020 7848 0025
Email:
Website:
Interests:
Inpatient care, and ways to reduce conflict (violence, absconding, substance use, rule breaking, and medication refusal) and containment (as required medication, coerced sedation, seclusion, special observation, manual restraint, etc.)
Tel:
020 7848 5323
Email:
Website:
Interests:
Use of services and outcomes for mothers and babies in perinatal psychiatry, systematic reviews in perinatal psychiatry, liaison psychiatry.
Tel:
020 7848 0851
Email:
Website:
Interests:
All aspects of mental health economics and policy, community care, social policy.
Tel:
020 7848 0174
Email:
Website:
Interests:
International mental health and epidemiology; dementia and retirement in developing countries.
Interests:
Social work and social care in mental health services
Social capital and social inclusion theory, practice and research
Social interventions in mental health
Pedagogical research in postgraduate education related to mental health
Tel:
020 7848 5096
Email:
Website:
Interests:
Depression, developing countries, epidemiology, international mental health, migration.
Tel:
020 7848 0136
Fax:
020 7848 0283
Website:
Interests:
Epidemiology, statistics.
Tel:
020 7848 0108
Fax:
020 7848 5056
Email:
Website:
Interests:
Personal recovery, outcome measures (Camberwell Assessment of Need, Threshold Assessment Grid), routine outcome assessment - further information at researchintorecovery.com.
Tel:
020 7848 0795
Email:
Website:
Interests:
Health service evaluation (PRiSM); special hospital statistics; cluster analysis.
Tel:
020 7848 0710
Email:
Website:
Interests:
Economic evaluation of mental health services, economics of forensic services, cost of child psychiatric services.
Tel:
020 7848 0874
Email:
Website:
Interests:
Personality disorder in primary care.
Tel:
020 7848 0568
Email:
Website:
Interests:
Mental health policy; services; primary care; prison health care; outcome indicators; suicide.
Tel:
020 7848 0383
Email:
Website:
Interests:
Vascular risk factors for dementia and cognitive decline; cognitive decline and dementia in UK ethnic minority groups, particularly African-Caribbean migrants.
Tel:
020 7848 0240
Email:
Website:
Interests:
Economic evaluation of mental health and social care services, including services for children and adolescents
Tel:
020 7848 0043
Email:
Website:
Interests:
Applying sound epidemiological methodology to health services research, particularly in old age psychiatry. Specific work includes: the development and evaluation of interventions for depression in later life; non-biological dementia and carer research; randomised controlled trials; and service evaluation. This is combined with general population-based epidemiological studies such as the neuropidemiology of Tourette Syndrome, the aetiology of squalor, and somatisation of the elderly.
Tel:
020 7848 0012
Email:
Website:
Interests:
Social factors in the aetiology and treatment of common mental disorders.
Tel:
020 7848 5062
Email:
Website:
Interests:
Senior Lecturer in Neuroimaging specialising in image registration, analysis and visualisation.
Tel:
020 3228 3043
Email:
Website:
Interests:
Reader in Neuroimaging with a strong interest in physiological imaging such as cerebral blood flow and metabolism.
Tel:
020 3228 3069
Email:
Website:
Interests:
Current research projects span neurodegeneration, epilepsy, stroke, psychosis, affective disorders, developmental disorders, and normal brain function, using a battery of neuroimaging techniques which include perfusion, diffusion, functional and structural imaging. Professor Barker’s personal research interests include the implementation and development of quantitative Magnetic Resonance Imaging (MRI) techniques including T1 and T2-mapping, Diffusion Tensor Imaging (DTI), and quantitative Magnetisation Transfer (MT) measurements, along with the application of such techniques.
Tel:
020 3228 3059
Email:
Website:
Interests:
Professor of Neuroimaging specialising in functional neuroimaging analysis and statistics Dr Andy Simmons - Reader in Neuroimaging specialising in neurodegeneration.
Tel:
020 3228 3051
Email:
Website:
Interests:
Senior lecturer in Neuroimaging with a strong interest in drug action on the brain.
Tel:
020 3228 3053
Email:
Website:
Interests:
Lecturer in Neuroimaging with a strong interest in pre-clinical applications and molecular imaging.
Tel:
020 7848 5451
Email:
Website:
Interests:
Head of Neuroimaging Department and Professor of Imaging Sciences with a strong interest in the translation of brain imaging techniques from the bench to the clinic.
Tel:
020 3228 3060
Fax:
020 3228 2116
Email:
Website:
Interests:
Lecturer in Neuroimaging specialising in image data analysis techniques
Tel:
020 3228 3052
Email:
Website:
Interests:
Cells (NSCs) and the neural progenitor cells (NPCs) that they generate is essential not only to our understanding of neurodevelopment but also in enabling us to harness the full potential of these cells for the treatment of neurodegenerative disease.

We study NSC/NPC biology in several ways.

1. We use a combination of cellular and molecular biology techniques to understand how growth in culture (in the presence of mitogens, including bFGF and EGF) influences gene expression profiles of NSCs/NPCs and hence their subsequent fate (see Price and Williams 2001; Bithell et al., 2005). The expression of key transcription factors that regulate NPC fate, and their ability to generate specific neural cell types is investigated over time in both primary cultures of NPCs and in NSC lines (immortalised and non-immortalised) isolated from different embryonic brain regions. Clonal lineage studies are carried out (see Williams et al., 1997; 1999) to determine whether all cells within a population respond similarly to growth in culture or whether the population is heterogeneous as regards gene expression profiles and developmental capabilities.

2. During forebrain development, gradients of morphogens (including SHH, BMPs, Wnts, and FGFs) direct the fate of NPCs by regulating the expression of specific sets of transcription factors. We are investigating whether different concentrations of morphogens, either alone or in combination, can be used to direct the fate of primary cultures of NPCs and NSC lines. Our goal is to be able to use this information to define culture conditions whereby NPCs/NSCs can be directed to generate a specific type of neuron or glial cell in a predictable manner.

3. We are investigating the signalling pathways that are involved in forebrain neurogenesis. During development, NPCs localised in different regions of the forebrain generate specific types of neurons. For instance, NPCs within the cortex generate mainly excitatory, glutamatergic neurons while NPCs within the ganglionic eminences generate mainly inhibitory, GABAergic neurons. These fate characteristics are maintained in primary culture when NPCs are given a neuronal differentiation signal such as Platelet-Derived Growth Factor BB (PDGF BB, see Williams et al., 1997). Using mutant and wild type chimeric PDGF receptors, together with inhibitors of particular downstream signalling pathways, we are attempting to identify which pathways are important for instructing NPCs from different regions to generate neurons.

4. We have an ongoing collaboration with Professor Noel Buckley, who will shortly join the CCBB at the Institute of Psychiatry, studying neurogenesis in the developing rodent forebrain (see Williams et al., 2004). At present we are investigating the role of the transcription factor REST in regulating gene expression and cell fate during neurogenesis and in differentiated neurons of the mouse forebrain. To do this we are generating mice carrying a floxed allele of REST (RESTfl/fl) in order to conditionally knock out this gene in the embryonic or adult brain by crossing RESTfl/fl mice with cre transgenic mice strains that will ablate the REST allele specifically in either the neuroepithelium or in differentiated forebrain neurons.

5. Other research in the laboratory involves studying the dysregulation of genes in psychiatric disorders. Here we specifically study the expression of a range of genes (both known and novel) that we have shown to be up- or down-regulated during neuronal differentiation (Bithell et al., 2003). This work is carried out in collaboration with Professor Ian Everall at the University of San Diego, USA.
Tel:
020 7848 0097
Email:
Website:
Interests:
Work in our research group focuses on mechanisms of nerve cell death in Alzheimer's disease and motor neurone disease (also known as amyotrophic lateral sclerosis -ALS). We are particularly interested in axonal transport and signal transduction in the nervous system since there is evidence that these processes are disrupted in Alzheimer's disease and ALS.
Tel:
020 7848 0393
Email:
Website:
Interests:
Tau, a microtubule-associated protein implicated in the development of pathology in Alzheimers disease, progressive supranuclear palsy and related tauopathies. This laboratory is particularly interested in the phosphorylation status of tau in disease and in the protein kinases involved in pathological and physiological phosphorylation of tau. Alpha-synuclein, a pre-synaptic protein present in Lewy bodies in the brain of people with Parkinsons disease, Dementia with Lewy bodies, multiple system atrophy and related disorders. Dr Hanger is investigating biochemical modifications and functional abnormalities in this protein and their implications for diseases in which alpha-synuclein plays a pathological role. A wide range of techniques is used in these research projects, including protein chemistry, cell and molecular biology. In conjunction with Proteome Sciences plc, we are also using new methods in mass spectrometry to investigate post-translational modifications of disease-associated proteins.
Tel:
020 7848 0041
Email:
Website:
Interests:
Research has focused on the evolution, development, and disease of the brain using Drosophila as a model system. These neurogenetic studies have significantly contributed to the identification of evolutionary conserved genetic mechanisms underlying insect and mammalian brain development, and which led to the current view of a common origin of the bilaterian brain. More recent research significantly contributed to the discovery of a new molecular pathway regulating neural stem- and progenitor cell self-renewal, which has a major impact for understanding cancer stem cell driven brain tumorigenesis as well as to devise new therapeutic strategies in regenerative medicine. Recent interests combine research in stem cell biology and neurodegeneration, and are directed towards the identification of genes and mechanisms regulating stem/progenitor cell proliferation and neuronal specification. These include research on stem cell self-renewal, brain tumor suppression, and Parkinson's disease.
Tel:
020 7848 0786
Email:
Website:
Interests:
Transplanted neural stem cells have a unique ability to restore the behavioural and structural deficits associated with chronic neural damage. Our group is engaged in studies to try to understand the biological basis of this repair process, and to translate this understanding into new therapies for intractable neurological disorders in patients.
Tel:
020 7848 0948
Email:
Website:
Interests:
Application of human genetics to the study of neurological and psychiatric disorders; in particular the neurological disorders, Alzheimer's disease and motor neurone disease and the psychiatric disorders schizophrenia and autism.
Tel:
020 7848 0630
Email:
Website:
Interests:
Neuropharmocology, neurophysiology. Please visit http://neuroscience.iop.kcl.ac.uk
Tel:
020 7848 0374
Email:
Website:
Interests:
Research has focused upon the neurobiology of Batten Disease or neuronal ceroid lipofuscinosis (NCLs). Batten disease is the collective name for a group of neurodegenerative childhood disorders that invariably prove fatal, with no effective treatment available. Together with colleagues in the US, Europe and New Zealand, we are working to discover precisely how Batten disease affects the brain. The main thrust of this work is to study patterns of neurodegeneration in mouse and large animal models of NCL, comparing our findings with the brains of affected individuals. In this manner we can identify and follow the earliest effects of disease and discover how and why these changes subsequently develop. These studies not only provide us with important landmarks of disease progression, but also the ability to judge the efficacy of candidate therapeutic strategies. Particular interests include: the comparative study of NCL pathogenesis; the role of neuroimmune and autoimmune responses in the NCLs and other storage disorders; the developmental neurobiology of the NCLs; assessment of therapeutic efficacy. Other collaborative studies with colleagues in the Institute's Neurodegeneration IRG continue to explore the role of novel proteins in neurodegenerative mechanisms.
Tel:
020 7848 0286
Email:
Website:
Interests:
Memory processes, including memory formation, storage, retrieval, and extinction, are fundamental for brain function and they are affected in various psychiatric illnesses such as mental retardation, Alzheimer's disease, and post-traumatic stress disorder. Currently, the biological basis of memory processes is not sufficiently well understood to develop successful treatments for memory dysfunctions. However, the advent of sophisticated molecular techniques now allows for an advanced analysis of memory processes in experimental animals, which promises to be translated for the patients.
Tel:
020 7848 5402
Email:
Website:
Interests:
Axonal transport, mitochondria, molecular motors, neurodegeneration.
Tel:
020 7848 0086
Fax:
020 7848 0017
Website:
Interests:
The main interest of Dr Modo's research lies in the restorative neurobiology following brain damage, with a particular interest in cerebral ischaemia and neurodegeneration. An interdisciplinary approach encompassing in vivo and ex vivo methods probes the functional, immunological, and histological consequences of brain damage. Our aim is to stimulate and/or supplement the potential of endogenous repair mechanisms to promote improvements in behavioural impairments. To this end, we also study the neurobiology of brain development/degeneration and its relation to neoplastic formations. Recent research efforts are aimed to use non-invasive methods, such as neuroimaging (MRI and PET), to visualise brain damage and how restorative strategies (such as stem cell migration and integration) lead to functional improvements after insults to the brain. Especially the developments in molecular imaging currently under way promise new vistas to probe the repair of the central nervous system in vivo. These novel imaging methods will provide us with means to link anatomical, metabolic, immunological, and functional changes in damaged brains to behavioural impairment and recovery.
Tel:
020 7848 0524
Email:
Website:
Interests:
Schizophrenia is a common, yet severe, psychiatric condition, affecting nearly 1% of the world population. The symptoms that define the disorder are diverse and variably expressed, and include disorganised thought, delusions, auditory hallucinations, mood disturbances and social withdrawal. Schizophrenia typically has an onset in early adulthood, and carries enormous costs to sufferers, their families and the wider society . Anti-psychotic medication remains the principal treatment for schizophrenia, although this can produce adverse side effects and generally alleviates only certain symptoms of the disorder.
Tel:
020 7848 5409
Email:
Website:
Interests:
Our interests are focused upon the transcriptional programs that operate to regulate neuronal gene expression. During embryonic life most of our 100 billion nerve cells are born. They are derived from neural stem cells, multipotent cells that have the potential to turn into any type of nerve cell. There are hundreds if not thousands of types of nerve cell - each type differing in its shape, connectivity and chemistry. This diversity of form, or phenotype, is essential to correct formation and functioning of the nervous system. Establishment and maintenance of phenotype requires that particular sets of genes are activated whilst others are shut down. Gene activity is regulated by transcription factors - proteins that bind to specific sets of genes and act as on/off or dimmer switches and microRNAs - short RNA molecules that switch off gene expression by destabilizing mRNA or blocking its translation. To date, our knowledge of how these 'transcriptional programmes' are established in nerve cells is almost non-existent. In no case do we know the complete set of targets of any singular transcription factor. One 'switch' we use for our studies is REST, a multifunction transcription factor that represses or silences many genes in both neural, and non-neural cells and is required for normal embryogenesis and development of the heart, as well as for neural stem cell differentiation. Furthermore, the regulation of REST and its target genes play important roles in several neuropathological conditions, including the response to ischaemic or epileptic insults, Down's syndrome, Huntington's disease and in some medulloblastomas. We have used bioinformatic approaches to identify all potential REST binding sites and target genes across multiple vertebrate genomes. Using chromatin immunoprecipiatation (ChIP) combined with DNA microarrays we can identify which target genes are operated on in which cell type and furthermore, we can map the epigenetic signature around theses sites. Combined with manipulating and measuring gene expression we are building up a profile of the cofactor platforms and chromatin modifications associated with each site. The application of this combined biochemical and bioinformatics approach allows several fundamental questions to be addressed: How many REST binding sites are there across the entire genome? Which genes are operated on in which cell types? Does this change with developmental stage? How does co-factor recruitment vary across different loci? Is this the cause or effect of distinct 'epigenetic signatures'? Currently, we are applying these approaches to neural stem cells to see how the epigenetic signature changes during neuronal and glial differentiation. Is the multipotentiality of a neural stem cells reflected in its chromatin structure? How does this change as commitment and differentiation proceed? Another application of this approach is the study of transcriptional dysfunction during neurological illness. For these studies we focus on the interaction between REST and huntingtin, an interaction that is disrupted in the presence of the mutant huntingtin allele leading to decreased expression of specific genes such as BDNF, a vital survival factor for striatal neurons. This gives a genome-wide perspective on transcriptional dysfunction in Huntington's disease and can potentially identify biomarkers or therapeutic targets.
Tel:
020 7848 0784
Email:
Website:
Interests:
Notch signalling in memory and Alzheimer's disease.
Tel:
020 7848 5245
Email:
Website:
Interests:
Mutations in presenilin 1 (PS1) may account for -50% of all familial Alzheimer's disease (FAD) cases. Recently, we identified PS1 as a scaffold protein regulating the sequential phosphorylation of beta-catenin by PKA and GSK-3beta, which is required for the efficient degradation of beta-catenin by the proteasome. PS1 FAD mutations represent a loss of this function and lead to deficient beta-catenin phosphorylation and degradation, resulting in cell cycle abnormalities that are secondary to abnormal beta-catenin accumulation. This phenotype is present in the brain of transgenic mice harbouring PS1 FAD mutations and our laboratory is actively investigating its implications for the pathology of PS1-linked FAD.
Tel:
020 7848 0578
Email:
Website:
Interests:
Research over the last 5 years has firmly established that learning and memory abilities, as well as mood can be influenced by diet. Although the mechanisms by which diet modulates mental health are not well understood. One of the brain structure associated with learning and memory as well as mood is the hippocampus. Interestingly, the hippocampus is one of the two structures in the adult brain where the formation of newborn neurons (or neurogenesis) persists. The level of neurogenesis in the adult hippocampus has been linked directly to cognition and mood. Therefore modulation of adult hippocampal neurogenesis by diet emerges as a possible mechanism by which nutrition impacts on mental health. In the Thuret Lab, we are studying the mechanisms by which diet modulates adult hippoacampal neurogenesis and impact on cognition and mood. If you want to know more about The Thuret lab please visit our webpage: http://www.iop.kcl.ac.uk/departments/?locator=622&context=872
Tel:
020 7848 5405
Fax:
020 7848 5407
Email:
Website:
Interests:
We are particularly interested in the relationship between tau phosphorylation, aggregation and filament formation during the development of pathology in Alzheimers diseaseand related tauopathies, and are examining the impact of protein kinase inhibitors as potential therapeutic agents for the treatment of tauopathy.
Tel:
020 7848 0087
Email:
Website:
Interests:
We use an embryonic stem (ES) differentiation model to explore NS cell formation process. To obtain the genes involved in this process, we have created a novel RNAi functional screening system, MARs (Mme I-assisted random shRNA). The obtained genes will be further investigated their biological functions in vivo. Stem cells with capabilities for self-renewal and generating a variety of tissue cells have seized people's attention. Especially, neural stem (NS) cells stand out in the crowd for their potential to treat the most intricate organ, the brain, in neurodegenerative diseases, genetic disorders, stroke, spinal injury and cancer. Progress has been made in harvesting NS cells from different sources and in transplanting NS cells to the needed regions of the central nerve system (CNS). However, the safety, effective use and limited supply of NS cells in neural repair remain as a hurdle for the therapeutic invention. The fundamental knowledge of the molecular programme directing NS cell development may bear solutions for those problems. Our project is undertaken to genome-wide screen for the genes involved in NS cell developmental process using a novel strategy. This strategy combines selective subtractive hybridisation to identify differentially expressed genes during NS cell developmental process and RNAi knockdown system to functionally screen for those genes involved in the developmental process. The understanding wholesale molecular programme responsible for NS cell formation may lead to develop drugs for NS cell survival, maintenance and proliferation.
Tel:
020 7848 5311
Email:
Website:
Interests:
Consultancy in proteomics and protein biomarker research
Consultancy in proteomics
Mass spectrometry-based proteomics
Protein biomarker research for NIHR Biomedical Research Centres

Interests:
Angela heads the Alzheimer’s disease RNA biomarker group that is part of a wider Alzheimer’s disease blood biomarker programme at the Institue of Psychiatry, headed by Professor Simon Lovestone.

The team aims to establish a robust panel of blood molecules within the next five years that together form a high performance biomarker, enabling early Alzheimer’s disease diagnosis and a way to accurately assess the rate of disease progression. A simple blood test for Alzheimer’s disease will ultimately enable personalised treatment strategies of individual patient response to treatments as they become available and enable treatment to begin at the earliest stage of disease where the greatest benefits can be achieved. It will also enable the effects of lifestyle and environmental factors to be monitored, which could lead to new health advice on how to prevent or slow progression of the disease.

In addition, the efficiency of a blood test would allow more drugs to be evaluated in clinical trials, thus increasing the chances of identifying and developing a desperately needed effective treatment for Alzheimer’s disease. Furthermore, this research could also have wider applications to other neurodegenerative disease, such as motor neurone disease and Parkinson’s disease, where common proteins to those implicated in Alzheimer’s disease are thought to be important in disease pathology.

Angela has also recently begun a pilot study to look for new ways to develop a treatment for Huntington’s disease. She is investigating how Dictyostelium discoideum (social amoeba) tolerate long polyglutamine-containing proteins that are found naturally in this organism which would be predicted to be disease-causing if produced in humans.
Tel:
020 7848 0772
Email:
Website:
Interests:
Dr Claudie Hooper currently holds a three year Alzheimer’s Society Fellowship to explore the role of inflammation in Alzheimer’s disease. Prior to this she worked on a Wellcome Trust project grant also at the Institute of Psychiatry and investigated the role of glycogen synthase kinase 3 (GSK3) in Alzheimer’s disease; particularly focusing on the Wnt and insulin signalling pathways (2004-2008).
Tel:
020 7848 0547
Interests:
My current research involves using multiple approaches to identify biomarkers for Alzheimer’s disease (AD) conversion, progression and treatment response. I am evaluating if smell identification test can be used as a treatment response marker in AD patients receiving cholinesterase inhibitors. I have further extended the project to establish whether smell identification has utility as a progression marker in AD. In a proteomics study in AD, I have identified plasma proteins differentiating rapid from non-rapid decliners, and validating them in larger samples for testing their robustness
Interests:
Current research activity
My fellowship is allowing me to conduct research into how we monitor disease progression in Alzheimer’s Disease. We hope to devise a sensitive and reliable method using functional magnetic resonance imaging.

Other research interests
I am involved in a study looking at the role of certain stages of sleep in the process of memory consolidation.

Tel:
020 7848 0346
Email:
Interests:
Ricardo Sainz-Fuertes is a Specialist Registrar in General Adult Psychiatry at The South London and Maudsley Trust (Guy’s rotation).

Dr Sainz-Fuertes is currently working under the supervision of Professor Robin Murray and Professor Simon Lovestone analyzing protein expression in plasma samples of patients suffering from Schizophrenia using Proteomic techniques such as Two-Dimensional gel electrophoresis (2DGE) and mass spectrometry (LS/MS/MS).

Interests:
Very late-onset schizophrenia-like psychosis. Psychosis that has onset after the age of 60 years is surprisingly common and our work has shown that this cannot be attributed to focal brain pathology or increased morbid risk among relatives but that increasing age, membership of a migrant group and difficulties with mentalisation can be added to the established risk factors of female gender and sensory impairment. We are continuing to explore how activity within the dopaminergic system changes with increasing age in females and investigating the utility of mentalising therapy, using film clips to train patients to understand social situations within which deception is involved. We are also about to begin recruitment to ATLAS (Antipsychotic treatment in very late-onset schizophrenia-like psychosis) which will be the first RCT to examine treatment in this group.

Brain imaging in dementia and psychosis. We were among the first groups to use functional brain imaging to locate activity associated with auditory and visual hallucinations and to investigate the substrate of visual imagery and motion perception and were the first to show that purely visual stimulation could activate auditory cortex and that hallucinatory activity was restricted to those brain areas whose activity supports perception. These findings have been used to explore the use of functional brain imaging to distinguish different dementia pathologies. Our main imaging approach to dementia has been to develop a paired associate learning stimulation paradigm which can be delivered to subjects during scanning at a number of different difficulty levels so that we can control for the confounds of performance success, relative and absolute difficulty. With this we have shown that young and old healthy subjects and patients with early Alzheimers disease all use the same brain areas to perform paired associate learning and that patients doing an easy task use the same brain regions that a healthy person would only have to use at a more difficult task level. These findings are currently being exploited to try and develop a robust biomarker of disease course progression in Alzheimers disease. To carry out more difficult levels of task, both patients and healthy comparison subjects recruit medial frontal regions - patients at easier levels than comparison subjects. We are currently investigating the sensitivity and reliability of just how early this frontal activation occurs and how it increases with increasing task difficulty in patients and healthy subjects scanned at 2 intervals separated by 6 months.

Independent large-scale randomised controlled trials. The evidence base used to support the use of most drug treatments in old age psychiatry is either modest or has been controlled by the pharmaceutical industry. Our work aims to change this situation through the identification of areas of genuine clinical uncertainty that can be tested through conduct of a trial. Some of the trials are still ongoing, but here is a sample with the questions that they hope to answer:

Is delirium preventable through training of general hospital staff to recognise and take steps to avoid emergence of symptoms? We carried out a trial of a staff education package within wards at Kings College Hospital and were able to halve the number of incident cases of delirium seen.

Is it possible to reduce the large proportion of nursing home residents with dementia who are routinely prescribed antipsychotic drugs? The FITS trial showed that provision of support to nursing homes in the form of 1 day per week of additional training reduced the proportion of residents prescribed antipsychotic drugs by 50%.

Do cholinesterase inhibitors have efficacy in the treatment of clinically significant agitated behaviour in people with Alzheimers disease? The CALM-AD trial showed unequivocally in 270 patients that these drugs were no better than placebo in the treatment of agitation although they did have a small positive effect on cognitive function.

Are the current NICE stopping rules for cholinesterase inhibitors correct? Should patients continue with their drugs once they have moderate to severe Alzheimers disease and do they benefit from adding memantine? The DOMINO trial begins recruitment in February 2008. To learn more about this trial visit http://neuroscience.iop.kcl.ac.uk/domino/
Are antipsychotic drugs superior to placebo in the treatment of patients with very late-onset schizophrenia-like psychosis? The ATLAS trial which commences recruitment in late 2010 will examine the effects of double-blind short-term (12 weeks) and longer term (26 weeks) treatment with amisulpride 100mg and placebo.

Can cognitive training improve cognition and slow down the rate of cognitive decline in mild Alzheimer’s disease? Together with Adrian Owen and colleagues in Cambridge we are developing an internet-deliverable cognitive training package based on the Cambridge Brain Gym (http://www.cambridgebraingym.com/tests.htm) which will be subject to a major RCT in the near future.

Can immunotherapy prevent or delay the appearance of Alzheimer’s disease in people with Downs Syndrome? Together with Tony Holland in Cambridge we are interested in investigating whether one of the current amyloid-based immunotherapy treatments can delay onset of symptomatic AD in this very high risk group.

Training and Standards in Psychiatry

As Dean of the Royal College of Psychiatrists (2008-13) I am the profession’s elected lead on training and professional standards. Within the College, I Chair the Education, Training and Standards Committee and the Heads of Schools Committee. Together with four Associate Deans, I have responsibility for the Curriculum, MRCPsych Examination and other assessments, Continuing Professional Development and Revalidation. As part of raising and maintaining standards in Psychiatry, I want us to attract the very brightest and best of trainees from all over the World to join us. In recent years, careers in Psychiatry have not been popular with UK medical school graduates. Changing undergraduate and foundation trainee perceptions about Psychiatry is an important ambition for the College and you can find out more about how we are doing this by visiting the College website.
Tel:
020 7848 0545/0550
Email:
Website:
Interests:
My research
My research interests concentrate on understanding the molecular and cellular events that take place in the brain and especially the role of tau, in Alzheimer’s disease, together with the genetics and proteomics of late onset Alzheimer’s disease. This work is sponsored by the Wellcome Trust, the Medical research Council, The Alzheimer’s Research Trust, the Alzheimer’s Society and Research into Ageing.

Pathogenesis of Alzheimer’s disease and the role of Glycogen Synthase Kinase-3 in the brain
In Alzheimer’s disease, the neuronal protein tau is more highly phosphorylated than in normal brain. Searching for the enzyme responsible for this phosphorylation led our group, and others, to the enzyme glycogen synthase kinase-3 (GSK-3). It is clear now that GSK-3 is not the only tau-kinase but it is perhaps the predominant kinase and we have shown that it is altered in Alzheimer’s disease and that it regulates long term potentiation (the closest model we have at a cellular level of memory). In cells we have shown that GSK-3 regulates tau binding to and stabilisation of microtubules and in Drosophila altering tau phosphorylation through GSK-3 inhibition restored axonal transport – a property of neurons essential for their normal function. All of this suggests that inhibition of GSK-3 might be a possible therapeutic option in Alzheimer’s disease.

We are now concentrating on understanding the regulation of GSK-3 in the brain. Our evidence suggests that GSK-3 regulation is altered in Alzheimer’s disease and possibly also in other neuropsychiatric conditions such as schizophrenia.

Biomarkers of Alzheimer’s disease
A biomarker, or test, for Alzheimer’s disease is urgently sought. Biomarkers are used elsewhere in medicine for improved diagnosis, for pre-symptomatic diagnosis, for risk evaluation, to monitor disease progression or the results of therapy. There are no fully confirmed biomarkers for AD although neuroimaging comes the closest and is widely used in both clinical practice and in research. For biochemical markers there is best evidence for CSF (spinal fluid) assays for tau protein or amyloid – both known to be involved in AD.

We have concentrated instead on trying to find a blood-based biomarker for AD. Using a candidate based approach and using proteomics we have found a range of changes in the blood of people with AD. This demonstrates that a blood based approach is feasible and we have confirmed some of these changes in large numbers of patients. We are now using these and related methods to find biomarkers that might be used in clinical trials and in clinical practice.

This research includes AddNeuroMed, one of the two related InnoMed projects that are pilots for the Innovative Medicines Initiative (IMI). Further details of IMI and AddNeuroMed can be found here.

Genetics of Alzheimer’s disease and other disorders

Together with John Powell at the IoP and collaborators in Cardiff I have been involved with large collaborative studies seeking to find genetic susceptibility factors for Alzheimer’s disease. Together this group has published many papers including a sibling-pair study finding a region on chromosome 10 linked to AD and a number of possible association findings including the first report of an association with Angiotensin Converting Enzyme. The IoP group has also reported associations of genetic factors with behavioural symptoms in AD and, in studies linking with our interest in intracellular signalling (see above), associations of genes involved in regulation of GSK-3 via wnt and insulin signalling with both Alzheimer’s and Schizophrenia.

My group
Many students, post-doctoral researchers and fellows have contributed to this work over the years. My current group are, in no particular order Richard Killick, Claudie Hooper, Graham Cocks, Anna Kinsey, Mirsada Causevic, Nicola Archer, Catherine Tunnard, Nicola Dunlop, Andreas Guntert, Madhav Thambisetty, Paul Hopkins and Ricardo Sainz Fuertes. Recent and much valued colleagues include Rejith Dayanadan, Amritpal Mudher, Eirini Meimaridou, Danae Liolitsa, Fiona Kerr, Abdul Hye and many others.
Tel:
020 7848 0239
Email:
Website:
Interests:
The main focus of my research interest is the neurochemistry of neuropsychiatric disorders in later life, with a view to understanding their pathophysiology and optimizing treatment strategies. I have a primary interest in psychosis within the context of neurodegeneration. My work to date has focussed upon the dopaminergic system of neurotransmission and has provided evidence that dopaminergic dysregulation is intimately associated with psychosis in Alzheimer’s Disease, similar to young adults with schizophrenia. Future PET studies aim to differentiate between age- and disease-related mechanisms of antipsychotic sensitivity in older people.

In addition to my own research, I oversee clinical trials in dementia, as part of my role within the Mental Health of Older Adults and Dementia Clinical Academic Group (CAG). We are also in the process of setting up an MSc in Dementia Care
Interests:
Amanda is Director of the Cancer Research UK London Psychosocial Group which studies the psychological and social aspects of cancer.
Tel:
020 7188 0907
Fax:
020 7188 0905
Email:
Website:
Interests:
General hospital psychiatry; King's Centre for Military Health Research.
Tel:
020 7848 5009
Email:
Website:
Interests:
Clinical psychopharmacology; neuroendocrinology and neurochemistry and functional neuroimaging (PET and f-MRI) of depression, chronic fatigue syndrome and aggression; neuroimaging of serotonin receptor function; biological effects of psychological therapies
Tel:
020 7848 5130
Email:
Website:
Interests:
Psychoneuroendocrinology, stress, immunity.
Tel:
020 7848 0807
Email:
Website:
Interests:
War and psychiatry and history of military psychiatry.
Tel:
020 7848 5413
Email:
Website:
Interests:
Eating disorders; functional magnetic resonance imaging (fMRI), genetic.
Tel:
020 7848 0564
Fax:
020 7848 0182
Website:
Interests:
The evaluation of psychological treatments particularly for eating disorders but also other areas such as substance misuse, depression and self-harm. His other areas of interest are family therapy, family interaction research and attachment.
Tel:
020 7919 2545
Email:
Website:
Interests:
Research interests encompass the causes and treatment of the various modern illnesses that afflict Western societies, such as electrosensitivity and multiple chemical sensitivity, and the psychological impact of terrorism. General Hospital Psychiatry- Mobile Phones Unit
Tel:
020 7346 3798
Email:
Website:
Interests:
Aetiological models of eating disorders including, culture, early development, neuroendocrine genes, life events and personality; neuroimaging and neuropsychology eating disorders; health services research, carers; behavioural and neuroendocrine studies of eating disorders.
Tel:
020 7848 3180
Email:
Website:
Interests:
Clinical supervision; education; psychotherapy.
Tel:
020 7848 0693
Fax:
020 7848 0287
Website:
Interests:
General hospital psychiatry.
Tel:
020 7740 5075
Email:
Website:
Interests:
Main research interest is neuropsychological, cognitive and emotional aspects of eating disorders. Current research includes new treatment strategies and cultural similarities and differences in illness perception and expression.
Tel:
020 7848 0134
Email:
Website:
Interests:
Understanding the depression-diabetes link; developing and evaluating interventions to improve diabetes control and depression.
Tel:
020 7848 5131
Email:
Website:
Interests:
Psychiatric epidemiology and liaison psychiatry with a special interest in service use; medically unexplained symptoms (including fatigue and chronic fatigue syndrome), and developmental risk factors for unexplained symptoms, depression in advanced disease and palliative care settings. Bereavement; effectiveness and cost effectiveness of antidepressants.
Tel:
020 7848 0778
Email:
Website:
Interests:
Memory disorders;neuro-imaging of patients with neuropsychiatric disorders; cognitive effects of pituitary lesions; calculation disorders; post-traumatic stress disorder.
Tel:
020 7188 5396
Email:
Website:
Interests:
Military/occupational epidemiology; risk taking behaviours and suicide. Currently involved in a large cohort study examining the health (mental and physical), lifestyle and career consequences of military deployments to Iraq and Afghanistan.
Tel:
020 7848 5265
Email:
Website:
Interests:
General hospital psychiatry; cognitive neuropsychiatry.
Tel:
020 7737 4000 x2492
Email:
Website:
Interests:
Unexplained symptoms and syndromes,such as chronic fatigue syndrome, gulf war syndrome and related issues. Main research at present is a long term cohort study of the physical and mental health of the British Armed Forces.
Tel:
020 7848 0796
Email:
Website:
Interests:
Addictions.
Tel:
020 7848 0263
Email:
Interests:
Perinatal psychiatry.
Tel:
020 7878 0353
Email:
Website:
Interests:
Epidemiological and aetiological studies of fatigue in adolescents and adults; evaluating the efficacy of cognitive behaviour therapy in chronic fatigue, CFS, irritable bowel syndrome and other somatoform disorders in adolescents and adults in primary and secondary care.
Tel:
020 7848 0406
Email:
Interests:
Eating disorders; deliberate self-harm; suicide prevention; personality disorders; aetiological factors; brief psychological treatments; new technologies in treatment; health services research.
Tel:
020 7848 3180
Email:
Website:
Interests:
Position: Aikaterini (Katerina) Fotopoulou is a lecturer in Cognitive Neuroscience and Neuropsychology at the Institute of Psychiatry. She is also an Associate Member at the Institute of Cognitive Neuroscience, University College London.

Biographical Note: Fotopoulou studied psychology in Athens (Greece); cognitive neuroscience, neuropsychology and theoretical psychoanalysis at University College London (UK); and conducted her PhD in these fields at the University of Durham (UK). She is currently also completing clinical doctorate training in psychotherapy (see below).

Research: Dr Fotopoulou's research focuses on topics and disorders that lie at the borders between neurology and psychiatry, aiming to understand the complex dynamic relation between mind and body. She is particularly interested in understanding how our physical body, our emotions and personal goals, as well as our relations with other people influence the function of our brain and ultimately shape how we understand ourselves and our new experiences. She conducts studies on self-consciousness, pain, emotions and memory in healthy volunteers, in patients that have suffered a stroke or other brain pathologies, as well as in individuals with psychological disorders such as somatisation, functional disorders, chronic pain and depression.

Research Fellowships, Awards and Grants: For these studies, and the many resulting publications in scientific peer-reviewed journals of international standing, Dr Fotopoulou was awarded an ESRC-MRC fellowship in 2005, a Neuropsychoanalysis Fellowship and the Clifford Yorke Prize for Early Career Contributions to Neuropsychoanalysis in 2006, as well as the Papanicolaou Prize from the World Hellenic Biomedical Society (2010). She was also recently awarded the British Neuropsychological Society's Early Career Award: The Elizabeth Warrington Prize (2011).

Finally, having won an earlier European competition of junior investigators (European Platform for Life Sciences, Mind Sciences and the Humanities ; supported by the Volkswagen Foundation), Dr Fotopoulou has more recently (2010) been awarded a further project grant from the Volkswagen Foundation to lead and coordinate an Interdisciplinary European Research Group that considers neuroscientific, psychological and philosophical perspectives in the study of interpersonal body awareness and pain perception. The London-based branch of this group has further won a project grant for the Hope for Depression Research Foundation (2010) to study the neural correlates of these effects in depressed patients.

Clinical Interests, Training and Activities: Dr Fotopoulou is completing a 4-year Doctorate Degree in Counselling and Psychotherapeutic Psychology, accredited by the British Psychological Society. This degree provides formalisation to her long standing interest and extensive volunteer placements in neuropsychological rehabilitation and translational research.

Dr Fotopoulou has been a member of the Neuropsychoanalysis Society's executive and organizational committee since 2003 and has run a monthly Neuropsychoanalysis and Psychodynamic Neuroscience group in London since September 2009. In 2007 she and Professor Martin Conway were awarded a grant from the British Economic and Social Sciences Council to host a two-year long seminar series in London. Bringing together distinguished scholars and researchers from the fields of psychology, neuroscience and psychoanalysis, the resulting publication (Eds. A. Fotopoulou, D. Pfaff & M.A. Conway), entitled 'From the Couch to the Lab: Trends in Psychodynamic Neuroscience' is due to be published by Oxford University Press in March 2012.

Tel:
020 7188 0183
Email:
Interests:
Cognitive, behavioural and physiological factors in aetiology and treatment of post-traumatic stress disorder.
Tel:
020 7848 5033
Email:
Website:
Interests:
My current research interests cover menopause, body image and the impact of attitudes towards bodily symptoms and/or illness, with a particular focus on developing evidenced based interventions in these areas.
Tel:
0207 188 9558 / 077223 28638
Email:
Interests:
To investigate the causal role of cognitive processes (e.g. imagery, worry, interpretation, attention and working memory) involved in the maintenance of anxiety disorders such generalised anxiety disorder and social phobia, and to develop interventions to ameliorate these problematic processes and thus reduce anxiety and distress.
Tel:
020 7848 0697
Email:
Website:
Interests:
Cognitive models of delusions and hallucinations; cognitive therapy for psychosis.
Tel:
020 7848 5003
Email:
Website:
Interests:
Cognitive processes in the maintenance and treatment of social phobia; post-traumatic stress disorder and panic disorder; virtual reality in the treatment of anxiety disorders; dissemination of psychological treatments.
Tel:
020 7848 0245
Email:
Website:
Interests:
Obsessive-compulsive (spectrum) disorder; anxiety; chronic fatigue; emotion; neuroimaging; neuropsychology; CBT; outcome predictors.
Tel:
020 7848 0543
Email:
Website:
Interests:
Body dysmorphic disorder, cosmetic surgery, obsessive compulsive disorder (OCD), vomit phobia.
Tel:
020 3228 3461
Fax:
020 3228 5215
Website:
Interests:
Clinical psychology; obsessive-compulsive disorder and post-traumatic stress disorder in adolescents; philosophical issues in psychology and psychiatry.
Tel:
020 7848 5011
Email:
Website:
Interests:
Evaluation of treatment trials in psychosis; family intervention and individual cognitive-behaviour therapy; cognitive processes in delusions and hallucinations; burden of care in psychosis; expressed emotion in carers, including staff carers; staff stress in mental health settings.
Tel:
020 7848 0232
Email:
Website:
Interests:
Medically unexplained symptoms, primary care mental health, health psychology applied to children.
Tel:
020 7188 0180
Email:
Website:
Interests:
Psychosis, including role of cognition and emotions in psychosis; psychological models of delusions and hallucinations; processes of change in CBT for psychosis; schizotypy and the continuum of mental illness; psychosis and spirituality.
Tel:
020 7848 0347
Email:
Website:
Interests:
Developing and evaluating CBT interventions for people with emotional and physical problems, anxiety, depression, emotional dysregulation, psychophysiology, neuropsychology.
Tel:
020 7188 9559
Email:
Interests:
Forensic psychology, reliability of evidence, false confessions, psychological vulnerabilities during detention, motivation for offending and attribution of blame.
Tel:
020 7848 0768
Email:
Website:
Interests:
The evaluation of psychological treatments particularly for eating disorders but also other areas such as substance misuse, depression and self-harm. His other areas of interest are family therapy, family interaction research and attachment.
Tel:
020 7919 2545
Email:
Website:
Interests:
Health psychology; illness cognition and self-regulation; stress and wound healing.
Tel:
020 7188 0180
Email:
Website:
Interests:
Dr Chilcot has particular expertise surrounding the psychological factors associated with chronic illnesses (e.g. End-Stage Renal Disease), including illness representations, psychological distress, health behaviour and outcomes (non-adherence and survival). His current research is focused on developing and evaluating psychological interventions in dialysis patients designed to improve psychosocial and clinical outcomes.
Tel:
020 7188 2597
Interests:
Large-scale health promotion; stress and depression workshops; development of psychoeducational approaches; primary care.
Tel:
020 7848 5004
Email:
Website:
Interests:
Neuropsychological aspects of epilepsy and other neurological / neuropsychiatric disorders; cognitive -behavioural treatment of epilepsy and non-epileptic (dissociative) seizures; psychological processes in adults with non-epileptic (dissociative) seizures; cognitive changes, neuroimaging, psychological impact and quality of life in Motor Neurone Disease.
Tel:
020 7848 5040
Email:
Website:
Interests:
Motor learning and motor control, movement disorders; neuropsychology of imagery, working memory, related cognitive functions and performance in neurological and neuropsychiatric disorders; neuroimaging.
Tel:
020 7848 0761
Email:
Website:
Tel:
020 7848 0416
Email:
Interests:
Developing and evaluating cognitive behavioural interventions in women's health, cardiology and oncology.
Tel:
020 7188 0180
Email:
Website:
Interests:
Chronic pain, cognitive behaviour therapy (CBT), insomnia, sleep.
Tel:
020 7848 5010
Fax:
020 7848 5037
Website:
Interests:
  • The attitude-behaviour relationship
  • Behavioural interventions
  • Motivation, cognition, and emotion
  • Dual-process models of cognition
  • Cognitive dissonance, self-affirmation, and information processing
  • Emotional intelligence
  • Mindfulness meditation and its cognitive and emotional benefits
  • Meta-cognition and self-knowledge
  • Persuasion and social influence
Email:
Interests:
Developmental/genetic disorders (eg autism, Williams-Syndrome); cognitive/behavioural phenotypes; adult outcomes.
Tel:
020 7848 0455
Email:
Website:
Interests:
Aetiology and treatment of post-traumatic stress reactions in children and adolescents.
Tel:
020 7848 0506
Email:
Website:
Interests:
Cognitive models of psychosis, delusions and hallucinations; cognitive behavioural therapy for psychosis.
Tel:
020 7848 5046
Email:
Website:
Interests:
Role of fronto-basal ganglia systems in neurological and psychiatric disorder; goal-directed behaviour; motivation; depression; functional imaging; impact of chronic disease on patients and carers.
Tel:
020 7848 0773
Email:
Website:
Interests:
Neuropsychology of executive and memory functioning; spatial orientation and hippocampal function in humans; investigation of memory using functional magnetic resonance imaging; the cognitive neuropsychology of schizophrenia.
Tel:
020 7848 0849
Email:
Website:
Interests:
(i) Using cross sectional, prospective and experimental methods to develop models which help us conceptualise and treat medically unexplained conditions such as chronic fatigue syndrome (CFS), irritable bowel syndrome (IBS) and post concussion syndrome.

(ii) Understanding adjustment to chronic illness from both the patient and family perspectives.

(iii) Developing self-management and CBT based interventions for people with chronic illnesses such as multiple sclerosis, IBS and CFS including telecare and web interventions.

(iv) RCT's of psychological interventions.

(v) Exploring the role of people's perceptions and responses to their symptoms, illness and treatments in affecting outcome. Recent projects include developing measures of perceptions of multi-morbidity and children's perceptions of parental illness.

Tel:
0207 188 0180
Email:
Website:
Interests:
Childhood anxiety disorders; post-traumatic stress disorder, cognitive-behavioural treatment.
Tel:
020 7848 5011
Email:
Website:
Interests:

Behaviour change, including the use of financial incentives.

Emotional and behavioural responses to biomarker feedback.

Tel:
020 7188 0192
Email:
Website:
Interests:
Evaluation of treatments for psychosis; health service evaluations; group cognitive behaviour treatment for hallucinations, stigma and its effects, cognitive predictors of outcome in schizophrenia; models of cognition personality and individual differences; measurement and theory; social and political attitudes; sexual attraction, deviation and dysfunction; psychology as applied to performing arts.in psychosis and cognitive remediation therapy for schizophrenia; disordered language and psychoses; consumer involvement in research.
Tel:
020 7848 5040
Email:
Website:
Interests:
Neurobiology of cognitive and affective deficits and their treatment in Schizophrenia.
Tel:
020 7848 0233
Email:
Website:
Interests:
Causes of schizophrenia and autism.
Tel:
020 7848 5241
Email:
Website:
Interests:
My research uses advanced neuroimaging techniques – such as structural and functional Magnetic Resonance Imaging - to investigate the neural correlates of mental illness. The majority of my current projects involve the integration of neuroimaging with multi-modal machine learning in order to examine predictors of outcome in those at high risk for psychosis and treatment response in those who have developed the disorder.
Tel:
020 7848 0833
Email:
Website:
Interests:
Professor David has a wide and diverse range of research interests including schizophrenia, neuropsychiatry, medically unexplained syndromes and neuroimaging – both structural and functional. He is especially interested in the concept of insight in schizophrenia and how this relates to treatment compliance
Tel:
020 7848 0138
Email:
Website:
Interests:
My research focuses on the neurodevelopmental changes following early brain injury and on the identification of neuroanatomical biomarkers for psychiatric and cognitive outcomes in those at high risk. 

Tel:
020 7848 0133
Email:
Website:
Interests:
The focus of my research is in understanding the neurofunctional and neurochemical determinants of transition to psychosis in individuals at Ultra High Risk of developing psychosis. Using functional MRI, I aim to identify the neural correlates of the aberrant attribution of salience, whilst a unique multi-modal approach allows an investigation of the role that aberrant dopamine synthesis capacity has in the development of a salience dysregulation syndrome.

I am also interested in identifying biomarkers that can be used as predictors of treatment response within clinical trials.

Tel:
020 7848 0919
Email:
Interests:
Epidemiology of psychosis
Social factors in the aetiology, course and outcome of psychosis
Culture, ethnicity and mental disorder
Illness behaviour and health service utilisation
Philosophy and sociology of mental illness
Research methodology
Tel:
020 7848 0351
Fax:
020 7848 5056
Email:
Website:
Interests:
Obsessive-Compulsive and Related Disorders
Tel:
020 7848 0543
Email:
Website:
Interests:
My research focuses on the study of psychosis, mainly employing neuroimaging methods and connectivity analyses in combination with genetics.
Tel:
020 7848 0425
Email:
Website:
Interests:
My research focuses on biological markers of psychosis risk and their genetic basis. I have conducted extensive EEG experiments in patients with schizophrenia and bipolar disorder as well as populations at risk of developing these diseases. I have worked using family as well as twin designs. Other biomarkers I'm interested in include MRI and cognition as well as how these different markers relate to each other to model psychosis risk. I use these EEG, cognitive and MRI biomarkers as alternative phenotypes (in addition to a conventional case-control analysis) to identify genes involved in the risk of developing psychosis. I have published a number of candidate gene studies of the phenotypes described. More recently, in collaboration with colleagues across Europe and Australia, I am doing a genome wide association study (GWAS) as part of the Wellcome Trust Case Control Consortium and I am also starting work on a low coverage whole genome sequencing project in psychosis and its characteristic phenotypes.
Tel:
020 7848 0907
Email:
Website:
Interests:
After an intercalated BSc in Psychology and Basic Medical Sciences, Dr MacCabe qualified in medicine at the University of London in 1995 and completed his basic and higher specialist training in Psychiatry at the Maudsley Hospital from 1997 to 2004. He obtained a joint MRC/Department of Health Special Training Fellowship in Health of the population research in 2004, in collaboration with the Department of Medical Epidemiology and Biostatistics at Karolinska Institute, Stockholm. He obtained an MSc in Epidemiology from the London School of Hygiene and Tropical Medicine in 2006 and a PhD in 2008. In 2009 he was awarded a Clinical Senior Lectureship by the Higher Education Funding Council for England.


Dr MacCabe has been honorary consultant psychiatrist at the National Psychosis Unit since 2005, where he is responsible for treating inpatients with severe psychosis and conducting clinical trials.  Dr MacCabe is special advisor on psychosis to the mental health charity, SANE.


Dr MacCabe conducts research into the causes and consequences of psychoses using the tools of lifecourse epidemiology. Much of his research is conducted in collaboration with international partners in Sweden and elsewhere.  His research interests include cognitive function in schizophrenia and bipolar, and trajectories of cognitive function prior to illness onset, differences in cognitive function between schizophrenia and bipolar disorder, associations between high cognitive function, creativity and mental disorders, and fertility of patients with psychosis.  He also has a clinical interest in treatment refractory schizophrenia and conducts research in improving the safety, tolerability and effectiveness of antipsychotic drugs, particularly clozapine.  

Tel:
+44 (0)20 7848 0757
Email:
Website:
Tel:
0207 848 0415
Email:
Interests:
Currently active research interests include:
- interpretation bias modification;
- attentional processing in psychosis;
- emotion processing in psychopathy

Tel:
020 7848 5119
Email:
Website:
Interests:
Research interests include CBT for psychosis, early detection and early intervention, virtual reality, and the influence of social stressors on the onset of psychosis.
Tel:
020 7848 0958
Fax:
020 7848 0952
Website:
Interests:
Dr Patel's main research interest is in pharmaco-epidemiology for psychiatry and particularly for antipsychotic medication.

Dr Patel has worked as a co-investigator on the randomised controlled clinical trials and naturalistic clinical effectiveness studies for risperidone long-acting injection (RLAI). For her MD thesis, she conducted studies investigating attitudes and beliefs to depots of psychiatric nurses and psychiatrists, in London, Manchester and Hong Kong and a cross-sectional study of 222 patients in London which investigated patient attitudes to oral and depot antipsychotic medication. In part, this work was funded as a fellowship by the Medical Research Council (2002-2005). She then held a clinical lecturer position (2005-2010) and continued conducting observational outcome studies and attitudinal studies. She was also a Consultant Psychiatrist working on an acute female in-patient ward at the Bethlem Hospital (2007-2010).

More recently, she has developed new lines of research which include exploration of the use of drug plasma levels for antipsychotics in routine clinical practice. She is a co-author for a series of systematic reviews on drug plasma level research for second generation antipsychotics. She has also received funding from the NIHR, in the form of a prestigious Clinician Scientist fellowship, to conduct a randomised controlled trial for use of olanzapine plasma levels in the inpatient setting. She is also currently conducting an investigation of medication prescribing in a systematic sample of all adults commenced on the new compulsory supervised community treatment (SCT) legislation with one year follow up to explore clinical outcomes.

Dr Patel’s research interests also include insight and treatment adherence in schizophrenia.
Tel:
020 7848 5136
Email:
Website:
Interests:
Muriel Walshe is a lecturer and co-ordinator of the Maudsley Psychosis Family Study and the UCH/IoP Follow-up Study of infants born Preterm in the Department of General Psychiatry at the Institute of Psychiatry. She also Deputy Course leader for the MSc in Psychiatric Research. Her research focuses on the investigation of endophenotypes for psychosis. She is a psychoanalytical psychotherapist and an honorary psychotherapist in the Adult and Perinatal Sections of the Psychotherapy Department at the Maudsley Hospital.
Tel:
020 7848 0057
Email:
Interests:
Neural correlates of denial of illness in schizophrenia using fMRI
Tel:
020 7848 5137
Email:
Interests:
Dr Bray's research group, funded mainly by the Medical Research Council (UK), use a variety of techniques to explore the molecular and cellular mechanisms by which identified schizophrenia susceptibility genes confer risk to the disorder.
Tel:
020 7848 5409
Email:
Website:
Interests:
His research focuses on understanding the causes of mental illnesses and improving their treatment using PET and other functional imaging techniques.

Mental illnesses are a major cause of ill health and premature death. They account for four of the six leading causes of adult disability in the world and one in every ten hospital beds in the UK is for the treatment of psychotic disorders such as schizophrenia.

Current work in his Group focuses on:

* Understanding the brain changes that lead to the development of psychotic disorders, using multi-modal imaging with PET and fMRI to understand the receptor and other functional brain changes underlying these disorders

* Examining the effects of cannabis and other drugs on the brain, and the influence of common genetic polymorphisms on brain function to understand why some people are vulnerable to psychosis

* Determining why some patients respond to treatments and others don't

* Using novel approaches to diagnosing mental illnesses

* Developing preclinical models for future drug development

Tel:
020 7848 0080
Email:
Website:
Interests:
My main area of interest is the application of brain imaging to the study of the early stages of psychosis, and the relationship between brain, other biological risk factors for psychosis, and the biological effects of antipsychotics. I am using different imaging techniques such as structural and functional imaging, and diffusion tensor imaging to explore the role of the neurological abnormalities in schizophrenia, and the presence of brain changes and their progression in psychosis. I am also currently using multimodal imaging longitudinally to establish neuroimaging biomarkers that can be used as predictors of treatment response to antipsychotic drugs in patients at the first episode of a psychosis.

Tel:
020 7848 0590
Email:
Website:
Interests:
My research interests focus on the prodromal phases of psychosis. My aim is to identify the core psychopathological and neurobiological factors associated with vulnerability to psychosis and illness onset and to develop specific treatments accordingly.
Tel:
0207 848 0900
Email:
Interests:
Neurocognitive basis of auditory verbal hallucinations. This was the focus of my doctoral work and I have published extensively on this subject. This work has involved using functional neuroimaging and cognitive psychological techniques to study clinical and non-clinical subjects who are prone to hallucinations.

Neurocognition in individuals at high risk of developing psychotic illnesses. This work involves people with an ‘At Risk Mental State’, and the use of cognitive psychological and neuroimaging techniques, with a particular focus on memory function. I have recently been awarded a NARSAD young investigator award to pursue this work.

Pharmacological fMRI. Studies which combine functional neuroimaging with a pharmacological challenge, which provide a means of examining the influence of neurotransmitters such as 5HT and cannabinoids on cognitive and emotional processing. I am also currently involved in studies combining fMRI and PET data in clinical subjects.


Tel:
020 7848 0514
Email:
Website:
Interests:
Functional and structural neuroimaging, particularly in relation to cognitive function, genetics, the early phase of psychosis and psychotic symptoms.
Tel:
020 7848 0355
Email:
Website:
Interests:
My research initially focused on reasoning processes in delusions, and, in 1988, I was the first to identify the ’jumping to conclusions’ reasoning bias, since demonstrated to be consistently associated with delusions in psychosis and now considered to be a phenotype of delusion liability. My early work in delusions also characterised them as multi-dimensional phenomena, on a continuum with everyday beliefs, and involving emotional as well as cognitive processes. This re-conceptualisation of delusions gave rise to new research strategies, examining the continuities as well as differences between delusions and other beliefs in reasoning and other cognitive processes, and the development of a number of new theoretically derived measures (e.g. the Peters et al, Delusions Inventory (PDI), the Maudsley Assessment of Delusions (MADs)).

These findings also led on to the development of therapeutic approaches for psychotic symptoms, drawing on and adapting the new cognitive behavioural therapy for anxiety and depression of AT Beck and colleagues. I was one a small number of UK-based clinical researchers in the late 1980s and early 1990s who initiated this approach. Our research group, formed in the early 1990s, with Fowler, Kuipers, Dunn, Bebbington, and later Freeman, published one of the first controlled trials and manuals of Cognitive Behavioural Therapy for Psychosis. We have continued to work together and have conducted a number of influential clinical trials of this CBT approach.

I have long been interested in service development and involved in the implementation of research into practice. As Head of Psychology for the South London and Maudsley NHS Foundation Trust, I have developed and evaluated new services for people with psychosis, particularly early intervention services incorporating CBT. Recently I co-led, with Tom Craig, the first UK RCT which demonstrated clinical and social benefits of a community-based assertive outreach early intervention service. I have served as psychological interventions lead on the Guideline Development Group of the National Institute of Clinical and Health Excellence (NICE) Schizophrenia Guideline (2003) and the Schizophrenia Guideline Update (2009).

Alongside the work of evaluating CBT and implementation of research, our group has continued to develop theory and to conduct theoretically based investigations. We published a highly cited cognitive model of the positive symptoms of psychosis in 2001, which has been the basis for our recent empirical work into cognitive, social and emotional processes in psychosis
Tel:
020 7848 5046
Email:
Website:
Interests:
Rina graduated from Guy's, King's and St Thomas' School of Medicine in London in 2000 with a first class degree in Experimental Pathology and two distinctions in Medicine.

She worked at St Thomas' Hospital in London as a House Officer and then trained in Psychiatry as a Senior House Officer on the St George's rotation, before moving to the Institute of Psychiatry, KCL and the Maudsley Hospital as a Clinical Researcher and Honorary SpR in 2005 after attaining the MRCPsych in 2004.

In 2007 she was awarded an MRC Training Fellowship under the supervision of Professors Robin Murray and Matthew Hotopf. In the same year she received the British Medical Association (BMA) Margaret Temple Research Award.

In 2008 she obtained an MSc with distinction in Epidemiology at the London School of Hygiene and Tropical Medicine. Her PhD thesis was on the subject of Suicide and Premature Death following First Episode Psychosis. In 2011 Rina was named the Royal Society of Medicine's Young Researcher of the Year, she was also awarded a second grant from the BMA which funds her PhD student's research concerning Insight in Psychosis and Risk of Suicide.

After obtaining her CCT in General Psychiatry with sub-specialisation in Liaison Psychiatry, she has worked as an Honorary Consultant Psychiatrist for the National Affective Disorders Unit, providing second opinions in a tertiary referral service. Her clinical special interest is in bipolar affective disorder and the mental health of health care professionals.

Tel:
+44 (0)20 7848 0721
Email:
Website:
Interests:
My main activity is carrying out research into finding the causes of schizophrenia and bipolar disorder, and developing better treatments for these disorders. I also care for patients within the National Psychosis Unit at the South London and Maudsley NHS Trust. People with psychotic illnesses from across the UK come to see us for advice as outpatients and may be admitted to our in-patient unit.

I have supervised 33 PhDs and 5 MD Theses (with 100% success).
Tel:
020 7848 0100
Email:
Website:
Tel:
020 7848 0599
Email:
Interests:
Studying the role of brain receptors and neurotransmitters, and the effect of antipsychotic drugs on dopamine and serotonin in particular.
Tel:
020 7848 0424
Email:
Website:
Interests:
Dr. Sophia Frangou's research focuses on the investigation of the pathophysiological processes underlying psychosis using clinical, cognitive, and neuroimaging techniques. Dr. Frangou is currently a Reader in Psychiatry at the Institute of Psychiatry, King's College London.

Dr. Frangou graduated from the medical school of the University of Athens, Greece. She then obtained a master's in Neuroscience followed by a doctoral degree in endophenotypes for psychosis from the University of London in the UK. Dr. Frangou did her postgraduate psychiatry training at the Maudsley Hospital in London.

Dr. Frangou is Editor of "European Psychiatry", the official Journal of the European Psychiatric Association. She is a Fellow of the Royal College of Psychiatrists and of the European Psychiatric Association. She has served on the Council of the British Association for Psychopharmacology (BAP) and co-authored the BAP guidelines for the treatment of Bipolar Disorder and is currently Expert Reviewer for the Working Group on the Classification of Mood and Anxiety Disorders for the Revision of ICD-10 Mental and Behavioural Disorders. She is vice-president for the International Society for Bipolar Disorders, Secretary and founding member of the EPA Section of NeuroImaging and heads the Brain Imaging Network of the European College of Neuropsychopharmacology.

Tel:
020 7848 0425
Email:
Website:
Interests:
Interests include sleep in psychosis, the interface of anxiety/depression and psychosis, psychometrics of anxiety as applied across diagnoses.
Email:
Website:
Interests:
Focus on the mechanism of action of antipsychotics in preclinical models which involved pharmacological, behavioural, determination of brain receptor occupancy, immunohistochemical and neuroimaging techniques. This work is being continued under Prof. Kapur’s guidance at the Institute of Psychiatry.
Tel:
020 7848 0013
Email:
Website:
Interests:
My research within the CSI Lab examines the mechanisms underlying the development of psychotic symptoms in schizophrenia, using psychophysics, functional neuroimaging and therapeutics. My research activities are complemented by my clinical role as Consultant Psychiatrist at the National Psychosis Service based at Bethlem Royal Hospital.
Tel:
020 7848 0350
Email:
Website:
Interests:
Psychiatry, classification and measurement. Genetic and environmental risk factors for unipolar depression and bipolar disorder.
Tel:
020 7848 0888
Email:
Website:
Interests:
Developmental psychopathology; personality assessment; health psychology.
Tel:
020 7848 0937
Email:
Website:
Interests:
Conduct disorder; psychosocial risks for childhood disorders; childhood-adulthood continuities.
Tel:
020 7848 0470
Email:
Interests:

My research focus is the development and application of statistical methods in human genetics, to identify and characterise genes contributing to common, complex disorders. Current research includes genome-wide association studies and disease risk prediction using genetic and environmental factors.

Fax:
020 7188 2585
Email:
Website:
Interests:
Animal behaviour; molecular genetic techniques (mutation detection, genotyping and gene expression profiling).
Tel:
020 7848 0745
Email:
Website:
Interests:
Addiction; alcohol; animal models; behaviour genetics; cocaine; neurochemistry; psychopharmacology; schizophrenia.
Tel:
020 7848 0873
Fax:
020 7848 0866
Website:
Interests:
Psychiatry; addiction and molecular genetics.
Tel:
020 7848 0397
Email:
Website:
Interests:
Molecular genetics of eating disorders; schizophrenia and bipolar disorder.
Tel:
020 7848 0631
Email:
Website:
Interests:
Study of psychopathic tendencies combining cognitive neuroscience and behaviour genetic approaches.
Tel:
020 7848 0038
Email:
Website:
Interests:
Cognitive neuroscience, specifically studies of autism spectrum disorders and investigation of related typical and atypical developmental processes (e.g. social cognition, local-global processing, savant skills).
Tel:
020 7848 0928
Email:
Website:
Interests:
Statistical genetics; behavioural genetics: developing methods for analysing (selected) data.
Tel:
020 7848 0890
Email:
Website:
Interests:

Mood, psychosis and addiction biology and genetics; the genetics of complex psychiatric disorders and co-morbid disorders; genetic technologies and bioinformatics.

Tel:
020 7848 0409
Email:
Website:
Interests:
Addiction biology using genetics, molecular biological and neuroimaging techniques; pharmacogenetics.
Tel:
020 7848 5314
Email:
Website:
Interests:
Molecular genetics; high throughput association studies; epigenetics and sex differences in behaviour.
Tel:
020 7848 0018
Email:
Website:
Interests:
Statistical methods for analysing complex traits.
Tel:
020 7848 0662
Email:
Website:
Interests:
Epigenetics; the molecular basis for gene-environment interactions.
Tel:
020 7848 5433
Email:
Website:
Interests:
Genetic influences on cognition and behaviour; developmental disorders; attention deficit hyperactivity disorder.
Tel:
020 7848 0930
Email:
Website:
Interests:
Children's social emotional and sociocognitive development; parent - child, sibling and peer relationships; development of language and communication abilities; adjustment and development of children in step families.
Tel:
020 7848 0893
Email:
Website:
Interests:
Psychiatric pharmacogenetics and pharmacogenomics.
Email:
Website:
Interests:
Functional genomics, systems genetics, mouse behaviour.
Tel:
020 7848 0279
Email:
Website:
Interests:
Victimisation; mental disorders; antisocial behaviours and their development.
Tel:
020 7848 0647
Email:
Website:
Interests:
Behavioural phenotypes of genetics disorders.
Tel:
020 7848 5325
Email:
Website:
Interests:
Genetics of normal and abnormal behaviour including psychiatric disorders such as depression, schizophrenia and conduct disorders; research encompasses quantitative and molecular genetic approaches as well as the co-action and interaction of genes and environment.
Tel:
020 7848 0871
Email:
Website:
Interests:
Genetics of ADHD and related neurodevelopmental disorders; clinical and genetic studies of ADHD in adults; mapping genes in common complex neuropsychiatric disorders; functional studies aimed at delinating the brain processes that mediate genetic risk on ADHD.
Tel:
020 7848 0078
Email:
Website:
Interests:
Psychology; learning abilities and disabilities; quantitative and molecular genetics.
Tel:
020 7848 0893
Email:
Website:
Interests:
Developmental psychopathology; gene-environment interplay; antisocial behaviours and their development.
Tel:
020 7848 0837
Website:
Interests:
Child and adolescent psychiatry, quantitative and molecular genetics, epidemiology, lifespan development, psychological influences, resilience, neuropsychiatry, and school effectiveness.
Tel:
020 7848 0882
Email:
Website:
Interests:
Functional genetics. Research at the molecular and cellular levels, including analysis of signal transduction pathways, gene expressions, and genetic contributions, to study fundamental processes controlling neuronal function, and their abnormalities in neuropsychiatric disorders. A major focus of the research is drug addiction.
Tel:
020 7848 0528
Email:
Website:
Interests:
Natural history of antisocial behaviour from childhood to adulthood; intelligence; domestic violence; longitudinal research methodology; measurement of abnormal behaviour; neuropsychological assessment; behavioural genetics.
Tel:
020 7848 0936
Email:
Website:
Interests:
Behavioural genetic approaches to developmental psychopathology, particularly anxiety and depression. Links between normal and abnormal development, comorbidity and heterogeneity. Exploring mechanisms of risk and gene-environment interaction using molecular genetic and cognitive psychological approaches.
Tel:
020 7848 0863
Email:
Website:
Interests:
Statistical methods of gene identification for complex traits; microarray and proteomics experiments.
Tel:
+44 (0)20 7848 0827
Website:
Interests:
Control of gene expression in the brain; functional analysis of genetic polymorphisms that are associated with behavioural disorders using in vitro methods.
Tel:
020 7848 0741
Email:
Ursula.D'Souza@iop.kcl.ac.uk
Website:
Students in discussion